Haemonetics (HAE) estimates, price target were boosted at Benchmark. Shares are now seen reaching $49. New analyst also raised estimates, as the company has premium pricing power, Benchmark said. Buy rating.
Las Vegas Sands (LVS) price target was raised at J.P. Morgan to $72. Multiple positive near-term and longer-term catalysts, J.P. Morgan said. Overweight rating.
Merck (MRK) estimates were increased at BMO Capital through 2014. Company has a solid pipeline, and Januvia can continue to growth, BMO Capital said. Market Perform rating and $50 price target.M&T Bank (MTB) numbers were cut at BMO Capital. Shares are now seen reaching $121. Estimates were also reduced, given the company's new guidance, BMO Capital said. Market Perform rating. Noble (NE) estimates were raised at UBS. Reflect five new jackup contracts, said UBS. Price target is $41. Oasis Petroleum (OAS) numbers were increased at Sterne Agee. Estimates were boosted through 2015. Recent acquisition should add to earnings, Sterne Agee said. Buy rating and new $54 price target. Palo Alto (PANW) numbers were raised at BMO Capital. Shares are now seen reaching $50. Estimates were also increased, given better license and billings growth, BMO Capital said. Market Perform rating. Raytheon (RTN) estimates, price target were increased at Jefferies. Estimates were raised through 2014. Company is gaining market share and can continue to grow overseas, Jefferies said. Buy rating and new $87 price target. Zoetis (ZTS) was added to the US 1 List at Bank of America/Merrill Lynch. Profit margin acceleration story is underappreciated by the market, BofA/Merrill said. $36 price target. >To submit a news tip, email: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.